At Fauquier Health, we follow the recommendations of the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and the U.S. Food and Drug Administration (FDA) regarding COVID-19 treatment options for patients requiring hospitalization. When deemed clinically appropriate by a patient’s physician, we offer the below FDA approved treatment options:
- Dexamethasone (anti-inflammatory)
- Remdesivir (anti-viral)
- Baricitinib (anti-inflammatory)
When deemed clinically appropriate for patients not requiring hospitalization, we also can provide Sotrovimab, which is a Monoclonal Antibody (mAb) Therapy treatment that has been proven effective against the Omicron variant.
Consistent with NIH Treatment Guidelines, our COVID-19 order set does not include standard treatment with: